Compare · NVO vs SION
NVO vs SION
Side-by-side comparison of Novo Nordisk A/S (NVO) and Sionna Therapeutics Inc. (SION): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SION operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 120.1x SION ($1.60B).
- Over the past year, NVO is down 45.7% and SION is up 103.4% - SION leads by 149.1 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 5 for SION).
- NVO has more recent analyst coverage (25 ratings vs 9 for SION).
- Company
- Novo Nordisk A/S
- Sionna Therapeutics Inc.
- Price
- $41.01-4.51%
- $33.64-4.94%
- Market cap
- $191.82B
- $1.60B
- 1M return
- -10.44%
- -22.35%
- 1Y return
- -45.66%
- +103.45%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 8
- 5
- Recent ratings
- 25
- 9
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest SION
- Amendment: SEC Form 144/A filed by Sionna Therapeutics Inc.
- Director Thompson Peter A. sold $4,493 worth of shares (101 units at $44.49) as part of a pre-agreed trading plan (SEC Form 4)
- Director Orbimed Advisors Llc sold $4,493 worth of shares (101 units at $44.49) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Sionna Therapeutics Inc.
- Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences
- Amendment: SEC Form SCHEDULE 13G/A filed by Sionna Therapeutics Inc.
- Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by Sionna Therapeutics Inc.
- SEC Form 10-Q filed by Sionna Therapeutics Inc.
- Sionna Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition